Safety and Efficacy of ACEI in Alport Syndrome Patients With COL4A3/COL4A4/COL4A5 Variants
Status:
Not yet recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
Alport syndrome (AS) is the second most common monogenic cause of end-stage renal failure
(ESRF). AS is caused by variants in the COL4A3, COL4A4, and COL4A5 genes, which encode for
the a3, a4, and a5 chains of type IV collagen. This trial is a prospective, randomized,
controlled and multicenter trial. Mainly to assess the safety and efficacy of ramipril in
Alport syndrome patients with variants of COL4A3/COL4A4/COL4A5.
Phase:
N/A
Details
Lead Sponsor:
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine